Company: TYRA
Filing Date: 2025-05-08
Form Type: S-3
Source: 0001193125-25-116008
Chunk: 39

Company: Tyra Biosciences, Inc.
Filing Date: 2025-05-08
Form: S-3
Chunk 39
---
 agreement (the Sales Agreement) with TD Securities (USA) LLC (TD Cowen) relating to the sale of shares of our common stock, par
value $0.0001 per share, offered by this prospectus. In accordance with the terms of such Sales Agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $150,000,000 from time to time through TD Cowen
acting as our sales agent or principal.

Our common stock is listed on the Nasdaq Global Select Market under the symbol “TYRA”. On May 6,
2025, the last reported sale price of our common stock on the Nasdaq Global Select Market was $10.00 per share.

Sales of our common stock, if any, under
this prospectus will be made in negotiated transactions, including block trades or block sales, or at market prices by any method that is deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the
Securities Act of 1933, as amended (the Securities Act), including without limitation sales made through the Nasdaq Global Select Market or on any other existing trading market for our common stock, or by any other method permitted by law. TD Cowen
is not required to sell any specific amount of securities but will act as our sales agent using commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreed terms between TD Cowen and us. There is no
arrangement for funds to be received in any escrow, trust or similar arrangement.

The compensation to TD Cowen for sales of common stock sold pursuant to
the Sales Agreement will be up to 3.0 % of the gross proceeds of any shares of common stock sold under the Sales Agreement. In connection with the sale of the common stock on our behalf, TD Cowen will be deemed to be an “underwriter”
within the meaning of the Securities Act and the compensation of TD Cowen will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to TD Cowen with respect to certain liabilities,
including liabilities under the Securities Act or the Securities Exchange Act of 1934, as amended (the Exchange Act).

We are an emerging growth company
as that term is used in the Jumpstart Our Business Startups Act of 2012 and a smaller reporting company as defined under Rule 405 of the Securities Act, and, as such, are subject to certain